Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.08
-1.7000-3.28%
Post-market: 51.050.9700+1.94%19:30 EDT
Volume:487.92K
Turnover:24.66M
Market Cap:15.31B
PE:22.46
High:51.91
Open:51.91
Low:50.03
Close:51.78
52wk High:55.49
52wk Low:45.77
Shares:305.78M
Float Shares:305.78M
Volume Ratio:1.75
T/O Rate:0.16%
Dividend:2.12
Dividend Rate:4.23%
EPS(TTM):2.23
EPS(LYR):2.47
ROE:7.56%
ROA:2.91%
PB:1.63
PE(LYR):20.32

Loading ...

Bitcoin, Ethereum, XRP, Dogecoin Up 3% As Markets Hope For Iran War Settlement

Benzinga
·
Apr 23

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Emera price target raised to C$73 from C$72 at CIBC

TIPRANKS
·
Apr 20

S&P 500 Futures Drop In Premarket Trading; TopBuild, Imperial Oil Lead

Dow Jones
·
Apr 20

Singapore procuring more LNG as Iran war cuts some supply

Sing Yee Ong & Stephen Stapczynski / Bloomberg
·
Apr 20

Roche Initiates New Study for Elevidys Gene Therapy Following European Regulatory Feedback

Deep News
·
Apr 16

Press Release: Emera Incorporated Announces Dividend Rates for Series J and Series K First Preferred Shares

Dow Jones
·
Apr 16

Why Infleqtion Stock Trading Higher On Wednesday?

Benzinga_recent_news
·
Apr 16

Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing

TIPRANKS
·
Apr 14

Emera Maintains Quarterly Dividend at $0.7325 per Share; Payable Around May 15 to Shareholders of Record on May 1

MT Newswires Live
·
Apr 13

Press Release: Emera Declares Quarterly Dividends

Dow Jones
·
Apr 13

Press Release: Emera Teleconference on May 8 to Discuss Q1 2026 Results

Dow Jones
·
Apr 07

Oculis to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Apr 07

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?

Simply Wall St.
·
Apr 04

ABBISKO-B Shares Surge Nearly 10% on EMA Orphan Drug Designation for FGFR4 Inhibitor

Stock News
·
Apr 01

Press Release: BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Apr 01

Abbisko Wins EMA Orphan Drug Status for Liver Cancer Therapy Irpagratinib

TIPRANKS
·
Apr 01

ABBISKO-B (02256): FGFR4 Inhibitor Irpagratinib Receives Orphan Drug Designation from EMA for Hepatocellular Carcinoma Treatment

Stock News
·
Mar 31

MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential

TIPRANKS
·
Mar 31